Literature DB >> 2157788

Biochemical and clinical analysis of accumulated glycolipids in symptomatic heterozygotes of angiokeratoma corporis diffusum (Fabry's disease) in comparison with hemizygotes.

I Hozumi1, M Nishizawa, T Ariga, T Miyatake.   

Abstract

Angiokeratoma corporis diffusum (Fabry's disease) is an X-linked disorder of glycosphingolipid catabolism. Heterozygous females, although usually asymptomatic, are occasionally as severely afflicted as hemizygous males; recently we identified a heterozygous patient with cardiomyopathy and severe pain in the extremities. In order to elucidate the difference of the clinical features, we analyzed the glycolipid composition of the heart, liver, and kidney obtained from the patient and from a hemizygote. Gas-liquid chromatography revealed that globotriaosylceramide (Gb3) was markedly increased in the heart (32.4 times higher than control) and increased to a lesser extent in the liver and kidney (3.74 and 6.79 times, respectively). The pattern of Gb3 accumulation in the heterozygote, where the highest increases were seen in the heart, was distinct from that in the hemizygote, where elevated levels of Gb3 and Ga2 were found in the kidney. Furthermore, the alpha-galactosidase activity in the heart, liver, and kidney of the heterozygote was 17%, 26%, and 36%, respectively, of normal controls, which correlated well with the accumulation of glycosphingolipid in the heart and with the disease's clinical manifestations. Two other hemizygotic patients, who were identified by low alpha-galactosidase activities, demonstrated the cardiac involvement.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2157788

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  11 in total

1.  Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease.

Authors:  R Schiffmann; G J Murray; D Treco; P Daniel; M Sellos-Moura; M Myers; J M Quirk; G C Zirzow; M Borowski; K Loveday; T Anderson; F Gillespie; K L Oliver; N O Jeffries; E Doo; T J Liang; C Kreps; K Gunter; K Frei; K Crutchfield; R F Selden; R O Brady
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

2.  [Globosides as key players in the pathophysiology of Shiga toxin-associated acute kidney failure and Fabry disease].

Authors:  S Porubsky
Journal:  Pathologe       Date:  2014-11       Impact factor: 1.011

3.  Interfering parameters in the determination of urinary globotriaosylceramide (Gb3) in patients with chronic kidney disease.

Authors:  Martina Gaggl; Marlene Hofer; Stefanie Weidner; Julia Kleinert; Günter Fauler; Manfred Wallner; Peter Kotanko; Eduard Paschke; Gere Sunder-Plassmann
Journal:  J Nephrol       Date:  2015-04-10       Impact factor: 3.902

4.  Aging accentuates and bone marrow transplantation ameliorates metabolic defects in Fabry disease mice.

Authors:  T Ohshima; R Schiffmann; G J Murray; J Kopp; J M Quirk; S Stahl; C C Chan; P Zerfas; J H Tao-Cheng; J M Ward; R O Brady; A B Kulkarni
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-25       Impact factor: 11.205

5.  Adeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of Fabry mice.

Authors:  S C Jung; I P Han; A Limaye; R Xu; M P Gelderman; P Zerfas; K Tirumalai; G J Murray; M J During; R O Brady; P Qasba
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-27       Impact factor: 11.205

6.  Leptomeningeal lipid storage patterns in Fabry disease.

Authors:  M Elleder; H Christomanou; B Kustermann-Kuhn; K Harzer
Journal:  Acta Neuropathol       Date:  1994       Impact factor: 17.088

7.  Clinical and biochemical studies in mucopolysaccharidosis type II carriers.

Authors:  I V D Schwartz; L L C Pinto; G Breda; L Lima; M G Ribeiro; J G Mota; A X Acosta; P Correia; D D G Horovitz; C G G Porciuncula; E Lipinski-Figueiredo; A C Fett-Conte; R P Oliveira Sobrinho; D Y J Norato; A C Paula; C A Kim; A R Duarte; R Boy; S Leistner-Segal; M G Burin; R Giugliani
Journal:  J Inherit Metab Dis       Date:  2009-10-10       Impact factor: 4.982

Review 8.  Fabry disease.

Authors:  Dominique P Germain
Journal:  Orphanet J Rare Dis       Date:  2010-11-22       Impact factor: 4.123

9.  Plasmalogens inhibit APP processing by directly affecting γ-secretase activity in Alzheimer's disease.

Authors:  Tatjana L Rothhaar; Sven Grösgen; Viola J Haupenthal; Verena K Burg; Benjamin Hundsdörfer; Janine Mett; Matthias Riemenschneider; Heike S Grimm; Tobias Hartmann; Marcus O W Grimm
Journal:  ScientificWorldJournal       Date:  2012-04-01

10.  Depletion of globosides and isoglobosides fully reverts the morphologic phenotype of Fabry disease.

Authors:  Stefan Porubsky; Richard Jennemann; Lorenz Lehmann; Hermann-Josef Gröne
Journal:  Cell Tissue Res       Date:  2014-07-04       Impact factor: 5.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.